NCT05399290

Subantimicrobial Doxycycline in Acne

A Randomized Controlled Trial Investigating the Pediatric Patient Experience of Subantimicrobial Dose Doxycycline for Acne Treatment

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: Michigan State University · Academic / Other
• Sex: All
• Age: 13 Years – 17 Years
• Healthy volunteers: Accepted

Summary

Antibiotic resistance is a public health problem that worsens the more physicians prescribe standard dose antibiotics for acne. Regardless of race, acne vulgaris is one of the most common dermatologic conditions among pediatric populations. As such, clinicians can make a large impact by practicing good antibiotic stewardship while still addressing the impact of acne on adolescents' self-esteem. Subantimicrobial doxycycline maintains its anti-inflammatory effects while eliminating antimicrobial properties and associated risks of drug resistance. Few studies, focused primarily on adults, have shown that subantimicrobial doxycycline is efficacious in treating acne from a physician standpoint. The investigators aim to investigate the patient experience of acne treatment with subantimicrobial dose doxycycline in the pediatric population.

Conditions

• Acne Vulgaris
• Pediatrics

Interventions

Type	Name	Description
DRUG	Doxycycline Hyclate	100 mg vs 20 mg doxycycline hyclate BID for 12 weeks

Timeline

• Start date: 2020-11-19
• Primary completion: 2021-11-08
• Completion: 2021-11-08
• First posted: 2022-06-01
• Last updated: 2023-04-03
• Results posted: 2023-04-03

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study